Mikael Dolsten — SPARQNOW

At-a-Glance

Served as Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer, Inc. from 2009 to 2024.
Led a team of over 8,000 scientists, overseeing global research operations across six therapeutic areas at Pfizer.
Under his leadership, Pfizer achieved over 35 drug and vaccine approvals, with more than half being New Medical Entities.
Received his medical degree and doctorate in tumor immunology from Lund University in Sweden, where he was also appointed Adjunct Professor.
Serves as a board member for public companies Agilent Technologies, Rocket Pharma, and Karyopharm Therapeutics.
Chairman of the boards of Orbis Medicines & Orogen Therapeutics, and a board director for several private biotechs including Enveda Bio, ChAi discovery, BenchSci, Marengo Tx, and ImmuneAi.
Senior advisor to business groups including Blackstone, GV Google Ventures, Bain & Co, Formation Bio, Canaan Partners, and Sutter Hill Ventures.

Biography

Mikael Dolsten is a Swedish-American physician scientist with a distinguished career in pharmaceutical research and development. Born in 1958 in Halmstad Municipality, Sweden, he earned his medical degree and a PhD in tumor immunology in 1988 from Lund University, where he was later appointed as an Adjunct Professor of Immunology.